EPS Diluted (Quarterly) Chart

Historical EPS Diluted (Quarterly) Data

View and export this data back to 2017. Start Trial.
Date Value
June 30, 2026 1.713
March 31, 2026 -0.5696
December 31, 2025 0.186
September 30, 2025 -0.624
June 30, 2025 -0.4814
March 31, 2025 -0.5059
December 31, 2024 -0.5026
September 30, 2024 -0.549
June 30, 2024 -0.7552
March 31, 2024 -0.3191
December 31, 2023 0.3178
September 30, 2023 -0.7442
June 30, 2023 -0.5344
March 31, 2023 -0.6243
September 30, 2022 -0.8343
June 30, 2022 -0.7606
March 31, 2022 -0.6976
December 31, 2021 -0.223
Date Value
September 30, 2021 -0.5874
June 30, 2021 -0.4551
March 31, 2021 -0.5371
December 31, 2020 -0.2506
September 30, 2020 -0.1728
June 30, 2020 -0.6875
March 31, 2020 -0.4282
December 31, 2019 -0.149
September 30, 2019 -0.3018
June 30, 2019 -0.6343
March 31, 2019 -0.6249
December 31, 2018 -0.7689
September 30, 2018 -0.5856
June 30, 2018 -2.29
March 31, 2018 -0.611
September 30, 2017 -0.3176
June 30, 2017 -0.2581
March 31, 2017 -0.245

EPS Diluted (Quarterly) Range, Past 5 Years

View EPS Diluted (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

EPS Diluted (Quarterly) Benchmarks

View EPS Diluted (Quarterly) Benchmarks
Start Trial
Xencor, Inc. -0.2864
UroGen Pharma Ltd. -0.2848
Ironwood Pharmaceuticals, Inc. 0.3068
Viking Therapeutics, Inc. -1.101
IDEAYA Biosciences, Inc. -1.222